Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
RPRX•Novartis Phase 3 pelacarsen trial misses primary endpoint
Sept. 4 (Reuters) - Royalty Pharma PLC RPRX.O:
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
- Royalty Pharma - Novartis Phase 3 HORIZON trial for pelacarsen fails to meet primary endpoint
- Royalty Pharma - expects to recoup investment and earn modest return despite pelacarsen failure
Source text: ID:nGNX9q42CV
Further company coverage: RPRX.O
